Study Design. Meta-analysis of individual patient data from randomized controlled trials of recombinant human bone morphogenetic protein-2 (rhBMP-2) in lumbar spinal fusion. Objective. To determine how patient characteristics impact estimates of effectiveness and harms of rhBMP-2 versus iliac crest bone graft (ICBG) in lumbar spinal fusion. Summary of Background Data. Patient characteristics are thought to impact rates of fusion in spinal fusion surgery, but no analyses examining the effect of patient characteristics on efficacy and safety of rhBMP-2 as compared with ICBG have been conducted. Methods. Using individual patient data obtained from the Yale Open Data Access Project, the impact of patient characteristics on the effects of rhBMP-2 on fusion, overall success, and harms were assessed using linear and generalized linear mixed effects models. Results. Ten industry-sponsored randomized controlled trials of rhBMP-2 were included in the analysis. There is preliminary support for an association between rhBMP-2 and improved outcomes for smokers (P ¼ 0.01), individuals under the age of 60 years (P < 0.01), and patients of normal weight (P ¼ 0.03), but not in patients who are nonsmokers, over the age of 60 years, obese or severely obese. RhBMP-2 usage was associated with decreased harms in individuals with no previous back surgeries but this was not seen in individuals with a previous back surgery (P < 0.01). Conclusion. Effects of rhBMP-2 may vary according to patient characteristics. Future studies of rhBMP-2 should include planned subgroup analysis in patients over 60 years, smokers, patients that are obese and severely obese, and individuals with previous back surgeries to better identify those most likely to benefit.
R ecombinant human bone morphogenetic protein-2 (rhBMP-2) is an orthobiologic developed as a bone graft substitute to promote spine fusion. As of 2006, it was a popular alternative to the standard of care, iliac crest bone graft (ICBG), being used in as many as 25% of all spinal fusion procedures. 1 As its popularity grew, adverse events were also increasingly reported in clinical practice, published reports, and unpublished data submitted for regulatory approval, [2] [3] [4] [5] and off-label use of rhBMP-2 in single-level posterior lumbar fusion in the United States decreased to less than 7% in 2010. 6 Recently two meta-analyses were conducted to provide more definite evidence on the overall effectiveness and harms of rhBMP-2 in spinal fusion using data from the literature and individual patient data (IPD) of rhBMP-2 trials 7, 8 provided by the manufacturer through the Yale Open Data Access (YODA) Project. 9, 10 These analyses found that as compared with ICBG rhBMP-2 had small or no benefit and a possible increase risk of harms, including cancer.
Few studies have evaluated the impact of patient characteristics on effectiveness and harms of rhBMP-2. One study comparing rhBMP-2 and ICBG by smoking status found that the use of rhBMP-2 did not improve outcomes as compared with ICBG in smokers and nonsmokers, but smokers had significantly lower rates of fusion that nonsmokers. 11 Another study of individuals over 60 years found that the use of rhBMP-2 improved outcomes, but was not designed to compare the effects in older versus younger patients. 12 However, it is well-known that multiple patient characteristics could affect the outcomes of spinal fusion procedures. Increased risk of complications and poorer outcomes have been shown to be associated with obesity, [13] [14] [15] [16] diabetes, [17] [18] [19] multiple back surgeries, 20 smoking, 12, 21 and older age, 22, 23 whereas patients who were working preoperatively have significantly better outcomes after lumbar spinal fusion, 23 and females are less satisfied than males with the outcomes of surgery. 24, 25 Results on how these patient characteristics might impact the effectiveness and harms of rhBMP-2 could help to identify which patients are more likely to benefit from rhBMP-2. The availability of the IPD for rhBMP-2 trials provides best data to evaluate the impact of these patient characteristics. Therefore, the objective of the current analysis is to build on the recent meta-analyses 7, 8 to examine how patient characteristics may impact the effectiveness and harms of rhBMP-2 as compared with ICBG in lumbar spinal fusion.
MATERIALS AND METHODS

Data Source
Deidentified IPD from 17 studies were provided by the YODA project 10 explicitly for the purpose of this analysis. The analysis was restricted to 1255 patients from 10 randomized controlled trials (RCTs) of rhBMP-2 versus ICBG in lumbar spinal fusion via anterior lumbar interbody fusion (ALIF), posterolateral fusion lumbar fusion (PLF), or posterior lumbar interbody fusion (PLIF) procedures. Table 1 lists the included studies and the number of patients from each treatment arm. Additional details about these studies have been reported elsewhere.
7,26-33
Outcomes
We considered both effectiveness and harm outcomes. The primary effectiveness outcomes were overall success and fusion as previously described in Fu et al 7 (Table 2) . Overall success was the original primary outcome in most trials. Overall success and fusion were assessed at 6, 12, and 24 months after surgery. Secondary effectiveness outcomes were patient reported functional status measured using the Oswestry Disability Index (ODI), 34 Physical Component Summary (PCS), and Mental Component Summary (MCS) of the Short Form 36 (SF-36) Health Survey Harms. 35 These outcomes were assessed at 6 weeks and at 3, 6, 12, and 24 months after surgery; 24 month results were considered the primary endpoint.
Harms outcomes included overall adverse events (AEs), severe AEs (SAEs), device-related AEs, and AEs that were both severe and device-related. Overall AEs included any AEs that occurred during the study period. SAEs were defined as AEs that put the patient at immediate risk of death, required the removal of the implant or device, or those that limited the patient's ability to perform routine activities. Related AEs were those that were deemed by study medical staff to be caused by the device. All AEs were binary as to whether or not the participant had experienced one or more AEs and aggregated as up to 4 weeks and 2 years postsurgery.
Patient Characteristics
We a priori selected preoperative age, body mass index (BMI), number of previous surgeries, diabetes status, work status, smoking, and sex to evaluate for impacts on estimates of effectiveness and harms. Patient characteristics were chosen for analysis based on past research of clinical relevance, the amount of available data, and presence of between-patient variability. All characteristics chosen for analysis had less than 1% missing data and a sufficient number of patients in each level of the characteristics for meaningful analysis.
To obtain more clinically interpretable estimates, we categorized continuous patient characteristics (age and BMI). Age was dichotomized as <60 versus !60 years based on previous research in spinal fusion. 12 BMI was categorized based on the US Preventive Services Task Force classification (underweight <18.5, normal weight 18.5 to 24.9, overweight 25.0 to 29.9, obese 30.0 to 34.9, and severely obese BMI ! 35.0). 36 Less than 1% of patients was categorized as underweight and were grouped with the normal weight group. Smoking status was dichotomized as preoperative smoker versus nonsmoker. Missing data were either handled by using a ''missing'' category or imputed using the first postsurgery measurement (for BMI).
Statistical Analysis
Primary Outcomes: Success, Fusion, and AEs (Binary) To assess whether there was a differential treatment effect (rhBMP-2 vs ICBG) by a patient characteristic, we used a logistic mixed effects model for overall success, fusion, and AE outcomes. Treatment effects were treated as random because of presumed heterogeneity, and the interactions between the treatment variable and each patient characteristic were treated as fixed. 37, 38 Full model building procedures are detailed in Appendix Table 1 , http:// links.lww.com/BRS/B137. We were unable to construct models of ''related'' AEs or ''related, severe'' AEs because of the small numbers of these events.
Secondary Outcomes: Self-Reported Function (Continuous) For each secondary self-reported outcome, we analyzed data from all time points in one model to assess longitudinal change. A linear mixed effects model was used with two random effects to accommodate the hierarchical data structure, one accounting for the heterogeneity of the treatment effect between the studies (random treatment effects), and one accounting for the correlation among repeated measures at different time points within the same patient (random patient effects). Details on the model building procedure are included in Appendix Table 1 , http://links.lww.com/BRS/ B137.
The primary analysis used all data from the ALIF, PLF, and PLIF approaches. Sensitivity analyses were performed by repeating analyses separately for patients with ALIF and PLF where enough studies were available. Results were qualitatively similar to those from the primary analyses and not further reported.
Reported P values are two-sided. All analyses were performed with SAS 9.3 (SAS Institute Inc., Cary, NC).
RESULTS
Study Characteristics
Our analysis included 622 patients treated with rhBMP-2 and 593 patients treated with ICBG from 10 RCTs (Table 1) . Table 3 presents the overall distribution of patient characteristics and distribution by treatment group. Patient characteristics were equally distributed across treatment groups, except that the proportion of diabetics in the ICBG group was almost twice that of the rhBMP-2 group.
Primary Outcomes: Overall Success, Fusion, and AEs Results of impact of patient characteristics on treatment effect for effectiveness outcomes are reported in Table 4 , and full models across all outcomes and time points are included as Appendices 2-6, http://links.lww.com/BRS/B137.
For overall success, treatment effect differed by BMI at 24 months postoperative (P for interaction ¼ 0.03) ( Table 4) . Normal weight patients experienced significantly higher odds of success with rhBMP-2 versus ICBG (odds ratio, OR: 2.17, 95% confidence interval, CI: 1.36-3.44) with a proportion of success of 64% in the rhBMP-2 group and 46% in the ICBG group. For all other BMI groups, there was no benefit associated with the use of rhBMP-2.
For fusion success, treatment effect differed by age at 6 months (P < 0.01) and by smoking status (P ¼ 0.01) and BMI (P ¼ 0.01) at 24 months (Table 4) . On average, 84% of patients under the age of 60 years in the rhBMP-2 group and 67% in the ICBG group experienced fusion success, and patients under the age of 60 years experienced significantly higher odds of fusion with rhBMP-2 versus ICBG (OR: 3.17, 95% CI: 1.20-8.37). In contrast, there was no treatment difference for fusion success in patients over 60 years of age years (OR: 1.12, 95% CI: 0.37-3.37). Though the interaction between age and fusion success was not statistically significant at 12 months and at the primary end point of 24 months, estimates for fusion success still favored rhBMP-2 for patients under the age of 60 years at later time points; at 24 months, rhBMP-2 was also associated with higher likelihood of fusion in patients over 60 years of age (OR: 3.47, 95% CI: 1.31-9.22).
Furthermore, 91% of smoking patients in the rhBMP-2 group and 71% in the ICBG group experienced fusion; smoking patients had significantly higher odds of fusion success with rhBMP-2 versus ICBG (OR: 4.90, 95% CI: 2.42-9.91). There was no difference in rhBMP-2 versus ICBG in nonsmokers (OR: 1.45, 95% CI: 0.85-2.47).
At 24 months, there was also evidence for a differential treatment effect for fusion success by BMI. In normal weight and overweight patients, rhBMP-2 was associated with higher odds of fusion versus ICBG (normal weight OR: 3.14, 95% CI: 1. Treatment effects did not differ for overall AEs and severe AEs across patient characteristics. For ''related'' and ''related severe'' AE, the treatment effect differed according to prior back surgery status (Table 5 ). Patients without a previous back surgery had significantly reduced odds for related and related severe AEs when treated with rhBMP-2 as compared with ICBG (related AE, OR: 0.22, 95% CI: 0.09-0.51; related severe AE, OR: 0.09, 95% CI: 0.03-0.32, respectively), but for patients with at least one previous back surgery, the risk of AE was higher with the use of rhBMP-2 but not statistically significant (related AE, OR: 2.10, 95% CI: 0.86-5.09; related severe AE, OR: 1.41, 95% CI: 0.53-3.77, respectively).
Secondary Outcomes: Self-reported Outcomes Across all self-reported outcomes, treatment effects did not differ by any patient characteristic. Patients with rhBMP-2 had statistically significant improvement in the ODI and SF-36 Physical Component over patients with ICBG; however, this difference was not clinically meaningful (Appendix Table 4 , http://links.lww.com/BRS/B137).
DISCUSSION
Based on an analysis of IPD from RCT's, our results suggest that certain patient characteristics may be associated with differential treatment effects of rhBMP-2 versus ICBG. At 24 months, rhBMP-2 was associated with increased likelihood of fusion versus ICBG for smokers over nonsmokers and for patients of normal weight versus obese or severely obese patients, but in severely obese patients, rhBMP-2 may be less effective than ICBG. Age modified the effectiveness of rhBMP-2 versus ICBG early at 6 months with patients under the age of 60 years showing a clear benefit for fusion with rhBMP-2, but no difference in ICBG and rhBMP-2 for patients over 60 years. At 24 months, both patients under and over 60 years experienced better fusion with rhBMP-2, possibly indicating a delayed benefit of rhBMP-2 for older patients. RhBMP-2 was also associated with decreased device-related AEs at 2 years versus ICBG in individuals with no previous back surgeries.
These findings were generally consistent with previously published studies. Although the effects of smoking on recovery in spinal fusion appear multifactorial and inconclusive, 11 one study in animal models found that the All of the following criteria must be satisfied: Evidence of continuous trabecular bone growth connecting the vertebral bodies and/or through 1 or both implants Absence of radiolucency covering >50% of implant. Translation of 3 mm and angulation of <5 degrees All were determined by CT scan or radiographs if CT scans were not available. Fusion PLF 8, [12] [13] [14] All of the following criteria must be satisfied: Evidence of continuous trabecular bone growth connecting the transverse processes Absence of radiolucent lines through the fusion mass Translation of 3 mm and angulation of <5 degrees All were determined by CT scan or radiographs if CT scans were not available presence of nicotine inhibits revascularization of the bone graft, 39 which could help to explain why smoking patients benefit more from rhBMP-2 than nonsmokers. There was also evidence that this process of revascularization during fusion occurred more slowly and with less success in smokers. 40 We also found that rhBMP-2 conveys a benefit in fusion and overall success for normal weight patients, but this benefit is not conveyed to patients of a higher weight, with a trend toward ICBG being more beneficial than rhBMP-2 in severely obese patients. It is possible that this is related to increased technical difficulties with surgery in obese and severely obese patients that negate any benefits of rhBMP-2 or additional comorbidities that impact responsiveness to rhBMP-2, such as a propensity to have more complications including impaired wound healing [13] [14] [15] [16] or having higher reported impairment before surgery. 13 Previously, rhBMP-2 has been found to be effective in patients over 60 years of age, 12 which was consistent with our findings at the primary endpoint (24 months). However, the differential effect of age on treatment occurred only at the first follow-up (6 months) in which patients under the age of 60 years (but not patients over 60 yrs) show a benefit from rhBMP-2. It is possible that certain complications associated with rhBMP-2, such as osteolysis, may contribute to the early differential effect of age on fusion. 12 Our findings indicate a significant reduction in the odds of device-related and device-related severe AEs with the use of rhBMP-2 in persons without prior back surgeries, but this benefit does not extend to patients who have had previous back surgeries.
Interestingly, treatment effects of rhBMP-2 were not impacted by any of the patient characteristics for the patient reported functional outcomes, despite some evidence of differential treatment effects in overall or fusion success. Therefore, the clinical significance of the differential treatment effects on overall or fusion success is uncertain.
Strengths and Limitations
IPD are ideal for conducting subgroup analysis on the impact of patient characteristics on treatment effects. 41, 42 Data included in this analysis represented over 90% of trial data existing for rhBMP-2 use in spinal fusion, minimizing reporting and related biases. IPD also allow for defining outcomes in a consistent way across studies and for modeling longitudinal trends using a mixed effect model controlling for multiple variables and potential confounders. Importantly, the use of IPD avoids the ecological fallacy that can occur when performing meta-regression with studylevel aggregated data. 42 The dataset was robust in that there was little missing data for patient characteristics.
In addition to use of IPD, other features make the current analysis well suited for evaluation of subgroup effects. [43] [44] [45] [46] We analyzed a relatively small number of prespecified patient characteristics that were assessed at baseline before treatment, based on evidence suggesting potential differential treatment effects. 44 Further, we tested for a treatment effect at multiple time points, allowing us to identify trends or effects that may vary over time. Although data came from trials that were not designed to assess subgroup effects, including data from multiple studies increased the statistical power to detect differences in subgroups.
Potentially the largest limitation of the evidence is that the 10 included RCTs were clinically heterogeneous with differing surgical approaches; however, such clinical heterogeneity was controlled for in all analyses, and sensitivity analyses by ALIF and PLF showed qualitatively similar results, which could increase the applicability of the results. Second, whereas we included data from multiple trials in this analysis, the sample sizes in certain subgroups were still small, potentially resulting in imprecise estimates. For example, the number of severely obese patients in this analysis was limited in that only one study (Study 14) allowed patients with weight greater than 40% over ideal for age and height. Although we controlled for important confounders available in the IPD, there is always the possibility of residual confounding in such an analysis. Another limitation of the evidence is that for all trials, patients and medical professionals conducting the study were not masked to the treatment and outcome ascertainments, and the only portion of the study that was masked was the assessment of radiographic outcomes. As we expect any effect of unmasking to be consistent across subgroup categories, the effect of this on the current findings is likely minimal. Finally, for most of the significant findings of a differential treatment effect by patient characteristics, the findings only occurred at 24 months, but 24 months was the primary endpoint. Another possibility is that some findings could be spurious because of chance as a result of performing multiple subgroup analysis. Therefore, to be clinically convincing, our findings need to be replicated in future trials that are adequately powered to detect subgroup effects, in particular, on important clinical outcomes such as patient reported functions.
CONCLUSION
The findings from this meta-analysis of IPD suggest that effects of rhBMP-2 may vary according to certain patient characteristics. RhBMP-2 was associated with improved likelihood of fusion success for smokers, patients under 60 years, and normal weight patients (but not obese or severely obese patients); and was related to a decrease in device-related AEs in individuals with no previous back surgeries. Future studies on rhBMP-2 should measure these patient characteristics and evaluate subgroup effects in preplanned analyses. These findings, if replicated, could inform patient-specific recommendations regarding the use of rhBMP-2 in lumbar spinal fusion.
Key Points
The findings from this meta-analysis of individual patient data suggest that a differential treatment effect may exist for rhBMP-2 versus ICBG within some patient characteristics. We found preliminary evidence for improved fusion with rhBMP-2 at 24 months for smokers (but not nonsmokers) and normal weight patients (but not obese or severely obese patients). Supplemental digital content is available for this article. Direct URL citations appearing in the printed text are provided in the HTML and PDF version of this article on the journal's Web site (www.spinejournal.com).
